Product image of Linatin Met (Metformin Hydrochloride, Linagliptin) supplied by GNH India

Linatin Met

Active Ingredient:
Metformin Hydrochloride, Linagliptin
Origin:
EU

Linatin Met (Metformin Hydrochloride, Linagliptin)

Metformin Hydrochloride and Linagliptin, the active ingredients in Linatin Met, are antidiabetic agents presented as a fixed‑dose oral tablet for oral use. The combination lowers blood glucose by reducing hepatic glucose production, enhancing insulin sensitivity, and increasing incretin‑mediated insulin secretion in adults with type 2 diabetes mellitus.

GNH India supplies Linatin Met as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets with full documentation and quality assurance and timely delivery.

Manufacturer / TM Owner

Nobel Pharma Co., Ltd.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linatin Met, a fixed‑dose combination antidiabetic medication, is indicated for management of type 2 diabetes mellitus.

  • Type 2 diabetes mellitus: improves overall glycemic control and reduces HbA1c levels.
  • Hyperglycemia: lowers fasting plasma glucose and post‑prandial glucose excursions.
  • Inadequate response to metformin monotherapy: provides additional glucose‑lowering effect when metformin alone is insufficient.

How It Works

  • Metformin Hydrochloride decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity, while Linagliptin inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, prolonging the activity of incretin hormones (GLP‑1 and GIP) that enhance glucose‑dependent insulin secretion. The complementary actions result in reduced blood glucose levels in patients with type 2 diabetes.

Side Effects

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Diarrhea: increased bowel movements.
  • Abdominal discomfort: cramping or pain.
  • Headache: transient head pain.
  • Dizziness: light‑headed sensation.
  • Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic disturbance.
  • Severe hypoglycemia: especially when combined with insulin or sulfonylureas.
  • Pancreatitis: inflammation of the pancreas.
  • Hepatic dysfunction: elevated liver enzymes.
  • Severe skin reactions: such as Stevens‑Johnson syndrome.
  • Renal impairment: worsening kidney function.

Precautions & Warnings

Before initiating Linatin Met, consider the following precautions:

  • Renal function assessment: evaluate eGFR and monitor periodically.
  • Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment.
  • Hypoglycemia monitoring: watch for low blood sugar when used with insulin or sulfonylureas.
  • Pregnancy and lactation: use only if potential benefit justifies the risk.
  • Drug interactions: review concomitant medications for possible DPP‑4 inhibitor interactions.
  • Store at ambient temperature: keep in the original container, protect from moisture and heat.

Avoid Interactions

Linatin Met may interact with several medicines. Review the following:

Major Interactions (Avoid)

  • Concomitant insulin or sulfonylureas: may cause severe hypoglycemia.
  • Cimetidine: can increase linagliptin plasma concentrations.
  • Iodinated contrast agents in patients with renal impairment: risk of acute kidney injury.

Moderate Interactions (Monitor Closely)

  • Metformin with diuretics: may affect renal clearance of metformin.
  • Alcohol consumption: raises risk of lactic acidosis.
  • Rifampicin: may reduce linagliptin exposure, diminishing efficacy.

Frequently Asked Questions

Linatin Met is a fixed‑dose oral combination of metformin hydrochloride and linagliptin indicated to improve blood glucose control in adults with type 2 diabetes mellitus, typically as part of a comprehensive management plan that includes diet and exercise.

Metformin reduces hepatic glucose production and increases peripheral insulin sensitivity, while linagliptin blocks the DPP‑4 enzyme, prolonging the activity of incretin hormones that stimulate insulin release only when blood glucose is elevated. Together they lower fasting and post‑prandial glucose levels.

The specific dose of Linatin Met is determined by the prescribing clinician based on individual patient factors such as renal function, glycemic targets, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of Linatin Met in pregnancy or lactation has not been definitively established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Linatin Met product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with metformin alone, Linatin Met adds a DPP‑4 inhibitor, offering greater HbA1c reduction without the need for additional tablets. Unlike sulfonylureas, it carries a lower risk of hypoglycemia, and unlike GLP‑1 receptor agonists, it is an oral tablet rather than an injection.

Linatin Met should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and excessive heat. Keep the container tightly closed and out of reach of children.

Linatin Met is taken orally, usually once daily with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a full glass of water and not chewed or crushed unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis, particularly in patients with severe renal or hepatic impairment, and severe hypoglycemia when used with insulin or sulfonylureas. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or confusion occur.

Linatin Met is contraindicated in patients with known hypersensitivity to metformin, linagliptin, or any excipients, as well as in those with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, and certain liver diseases. Clinicians should assess each patient individually.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT